Gabapentin Capsule
Product Images NDC 71610-756

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-756). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 300 mg (71610 0753 94)

Bottle Label 300 mg (71610 0753 94)
FDA Label Image

Bottle Label 100 mg (71610 0756 30)

Bottle Label 100 mg (71610 0756 30)
FDA Label Image

Bottle Label 400 mg (71610 0757 53)

Bottle Label 400 mg (71610 0757 53)
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Equation (Equ)

Equation (Equ)
The given text appears to be a mathematical formula related to age, weight, and serum creatinine. It calculates the value by multiplying the difference between 140 and age (years) with weight (kg). Additionally, it calculates the value by multiplying 72 with serum creatinine (mg/dL). For female patients, an additional step of multiplying the result by 0.85 is mentioned.*
FDA Label Image

Fig 1 (Fig 1)

Fig 1 (Fig 1)
FDA Label Image

Fig 2 (Fig 2)

Fig 2 (Fig 2)
FDA Label Image

Fig 3 (Fig 3)

Fig 3 (Fig 3)
FDA Label Image

Fig 4 (Fig 4)

Fig 4 (Fig 4)
FDA Label Image

Structure (Struct)

Structure (Struct)
FDA Label Image

Table 1 (Tab 1)

Table 1 (Tab 1)
TABLE 1. Gabapentin Dosage Based on Renal Function This table provides dosing information for Gabapentin based on renal function. The dosage is adjusted based on the patient's creatinine clearance, which is a measure of kidney function. The table includes dosages for different levels of renal function, ranging from total dysfunction to normal function. The dosages are given in milligrams per day and are divided into different regimens, such as three times a day (TID), two times a day (BID), or a single daily dose (QD). For patients on hemodialysis, there is an additional supplemental dose recommended. The table also provides instructions for adjusting the dosage for patients with lower creatinine clearance.*
FDA Label Image

Table 2 (Tab 2)

Table 2 (Tab 2)
FDA Label Image

Table 3 (Tab 3)

Table 3 (Tab 3)
This is a list of adverse reactions reported in pooled placebo-controlled trials for the treatment of postherpetic neuralgia using Gabapentin. The reactions include asthenia (weakness), infection, accidental injury, digestive system issues such as diarrhea, dry mouth, constipation, nausea, and vomiting. There were also metabolic and nutritional disorders reported including peripheral edema, weight gain, and hyperglycemia. Nervous system reactions such as dizziness, somnolence (sleepiness), ataxia (loss of muscle control), abnormal thinking, and abnormal gait were reported. Additionally, there were respiratory system reactions like pharyngitis (sore throat), and special senses reactions including blurred vision, amblyopia (lazy eye), conjunctivitis (pink eye), and diplopia (double vision).*
FDA Label Image

Table 4 (Tab 4)

Table 4 (Tab 4)
FDA Label Image

Table 5 (Tab 5)

Table 5 (Tab 5)
FDA Label Image

Tab 6 (Tab 6)

Tab 6 (Tab 6)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.